Vertex Pharmaceuticals Incorporated Message Board
-
conference call summary?
Anyone wish to take a stab at summarizing the conference call (I cannot listen at work... will do my homework later)? Curious as to why our robust AH/post-release pricing is slipping a bit... Thoughts?
Thanks.-
This CC does not excite me. I bought back the options I just sold and sold the stock I had purchased awhile back at 30.7
It just doesn't seem like an exciting investment. I could see it getting carried up with the market but I can buy any stock for that. NASDAQ at a ten year high.
Flat INCIVEK sales for 2012. No CF data till mid year. I'm putting my money elsewhere. I think it will get hit hard if the NASDAQ ever sells off. -
Nothing that we did not know excepting that Vertex's estimated revenues from Incivek will come much lower than I assumed. They predict sales for Incivek of $1.5-1.7B in 2012, that reflects about $400/quarter. Months ago, most expectations were in the range of $2-$2.5B sales for Incivek, so that's a BIG difference.
We will see how the stock is reacting to that ...- 2 Replies to agnostinvesting
-
They predict sales for Incivek of $1.5-1.7B in 2012, that reflects about $400/quarter. Months ago, most expectations were in the range of $2-$2.5B sales for Incivek, so that's a BIG difference.
Hopefully that's already priced into the stock.
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_V/threadview?m=tm&bn=19596&tid=40147&mid=40149&tof=97&rt=2&frt=2&off=1 -
It was stated at the conference call that Vertex expects significant revenues from Incivo royalties in europe and sales of Kaydeco. They may still make the $2-$2.5 revenue figure when these revenue sources are combined with Incivek sales.
-